Reproductive Health Matters
Volume 16, Issue 32 , Pages 86-96 , November 2008

Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications

  • Sue J Goldie

      Affiliations

    • Roger Irving Lee Professor of Public Health and Director, Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston MA, USA
    • ,
  • Meredith O'Shea

      Affiliations

    • Research Scientist and Program Manager, Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston MA, USA
    • ,
  • Mireia Diaz

      Affiliations

    • Research Scientist, Unit of Infections and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology, and Department of Paediatrics, Obstetrics, Gynaecology and Preventive Medicine, Programme in Public Health and the Methodology of Biomedical Research, Universitat Autónoma de Barcelona, Barcelona, Spain
    • ,
  • Sun-Young Kim

      Affiliations

    • Senior Research Fellow, Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston MA, USA

References 

  1. Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine. 2006;24(S3):S11–S25
  2. Muñoz N, Bosch FX, Castellsagué X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. International Journal of Cancer. 2004;111(2):278–285
  3. Clifford G, Franceschi S, Diaz M, et al. HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006;24(S3):S26–S34
  4. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. International Journal of Cancer. 2007;121:621–632
  5. Denny L, Quinn M, Sankaranarayanan R. Chapter 8: Screening for cervical cancer in developing countries. Vaccine. 2006;24(S3):S71–S77
  6. Goldie SJ, Kuhn LK, Denny L, et al. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001;285:3107–3115
  7. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Cost-effectiveness of cervical cancer screening in five developing countries. New England Journal of Medicine. 2005;353(20):2158–2168
  8. Goldie SJ, Kim JJ, Myers E. Chapter 19: Cost-effectiveness of cervical cancer screening. Vaccine. 2006;24(S3):S164–S170
  9. Sankaranarayanan R, Gaffikin L, Jacob M, et al. A critical assessment of screening methods for cervical neoplasia. International Journal of Gynaecological Obstetrics. 2005;89(S2):S4–S12
  10. Ault KA Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369:1861–1868
  11. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247–1255
  12. Garnett GP, Kim JJ, French K, et al. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine. 2006;24(S3):S178–S186
  13. Goldie SJ. Chapter 15: Public health policy and cost-effectiveness analysis. Journal of the National Cancer Institute Monograph. 2003;(31):102–110
  14. Goldie SJ, Goldhaber-Fiebert JD, Garnett GP. Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine. 2006;24(S3):S155–S163
  15. Kim JJ, Brisson M, Edmunds WJ, et al. Modeling cervical cancer prevention in developed countries. Vaccine. 2008;26(11):K76–K86
  16. Goldie SJ, Kim JJ, Kobus K, et al. Cost-effectiveness of HPV16,18 vaccination in Brazil. Vaccine. 2007;25(33):6257–6270
  17. Goldie SJ, O'Shea M, Campos NG, et al. Health and economic outcomes of HPV16,18 vaccination in 72 GAVI-eligible countries. Vaccine. 2008;26(32):4080–4093
  18. Goldie SJ, Diaz M, Constenla D, et al. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine. 2008;26(S11):L59–L72
  19. Goldie SJ, Diaz M, Kim SY, et al. Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine 2008;26(S12):M17-29.
  20. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. British Journal of Cancer. 2007;97(9):1322–1328
  21. Kim JJ, Kobus KE, Diaz M, et al. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine. 2008;26(32):4015–4024
  22. Diaz M, Kim JJ, Albero G, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. British Journal of Cancer. 2008;99(2):230–238
  23. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 2008;26(3):191–215
  24. In:  Gold MR,  Siegel JE,  Russell LB, et al. editor. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996;
  25. World Health Organization. Macroeconomics and Health: investing in health for economic development: report of the commission on macroeconomics and health. Geneva: WHO; 2001;
  26. World Health Organization Statistical Information System. CHOICE (Choosing Interventions that are Cost Effective). At < www.who.int/choice/en/>. Accessed 29 January 2008
  27. Evans DB, Edejer TT, Adam T, et al. Methods to assess the costs and health effects of interventions for improving health in developing countries. BMJ. 2005;331(7525):1137–1140
  28. Disease Control Priorities Project (DCPP). At < www.dcp2.org/main/Home.html>. Accessed 28 January 2008
  29. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, et al. Modeling human papillomavirus and cervical cancer for analyses of screening and vaccination. Population Health Metrics. 2007;5(1):11
  30. Kim JJ, Kuntz KM, Stout NK, et al. Multiparameter calibration of a natural history model of cervical cancer. American Journal of Epidemiology. 2007;166(2):137–150
  31. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. New England Journal of Medicine 2008;359(8):821-32.
  32. Kou U. Guidelines for estimating costs of introducing new vaccines into the national immunization system. Geneva: World Health Organization, Department of Vaccines and Biologicals; 2002;
  33. World Health Organization. Adding a vaccine to a national immunization programme: decision and implementation. WHO/IVB/05.18. 2005. At: < www.who.int/vaccines-documents/DocsPDF05/777_screen.pdf>. Accessed 1 August 2008
  34. Goldhaber-Fiebert JD, Goldie SJ. Estimating the cost of cervical cancer screening in five developing countries. Cost Effectiveness and Resource Allocation. 2006;4:13
  35. International Labour Organization. LABORSTA online database. At: < http://laborsta.ilo.org/>. Accessed 21 September 2008
  36. Hu D, Bertozzi SM, Gakidou E, et al. The costs, benefits, and cost-effectiveness of interventions to reduce maternal morbidity and mortality in Mexico. PLoS ONE. 2007;2(1):e750
  37. Max W, Rice DP, Sung HY, et al. Valuing human life: estimating the present value of lifetime earnings, 2000. (October 1, 2004). Center for Tobacco Control Research and Education. Economic Studies and Related Methods. Paper PVLE2000. At: < http://repositories.cdlib.org/ctcre/esarm/PVLE2000/> Accessed 18 September 2008
  38. IAVI/PATH. HPV vaccine adoption in developing countries: cost and financing issues. At: < http://www.iavi.org/viewfile.cfm?fid=47496>. Accessed 29 February 2008
  39. Constenla D, Ortega-Barria E, Rheingans RD, et al. Economic impact of rotavirus vaccination in Panama. Anales de pediatría (Barcelona). 2008;68(2):128–135
  40. In:  Drummond MF,  Sculpher MJ,  Torrance GW, et al. editor. Methods for the Economic Evaluation of Health Care Programs. 3rd ed.. New York: Oxford University Press; 2005;
  41. Goldie SJ, Grima D, Kohli M, et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. International Journal of Cancer. 2003;106(6):896–904
  42. Kim SY, Salomon JA, Goldie SJ. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bulletin of World Health Organization. 2007;85(11):833–842
  43. World Bank. Regional fact sheet. World Development Indicators 2008: Latin America and the Caribbean. At < http://siteresources.worldbank.org/DATASTATISTICS/Resources/lac_wdi.pdf>. Accessed 11 September 2008
  44. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries–key challenges and issues. New England Journal of Medicine. 2007;356(19):1908–1910
  45. Haug CJ. Human papillomavirus vaccination – reasons for caution. New England Journal of Medicine. 2008;359(8):861–862
  46. Musgrove P, Fox-Rushby J. Cost-effectiveness analysis for priority setting. Disease Control Priorities in Developing Countries. 2006;271–283

PII: S0968-8080(08)32409-4

doi: 10.1016/S0968-8080(08)32409-4

Reproductive Health Matters
Volume 16, Issue 32 , Pages 86-96 , November 2008

Article Tools